First-Line Combo Yields Strong Results in Advanced Sarcoma
As a first-line regimen, the investigative intravenous combination of trabectedin plus ipilimumab and nivolumab is likely safe and effective for untreated advanced soft tissue sarcoma, according to 7-year data (2017-2024) from the ongoing phase 2 portion …